Trial Profile
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of Bosutinib in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Breast cancer; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Wyeth
- 17 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2009 Actual end date (1 May 2009) added as reported by ClinicalTrials.gov.
- 15 Jul 2009 Actual initiation date (1 Oct 2008) and trial location (Poland) added as reported by ClinicalTrials.gov.